Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 19
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Risk factors and clinical impact of multidrug resistance in healthcare-associated bacteraemic urinary tract infections, a post-hoc analysis of a multicentre prospective cohort in Spain

  • Gómez-Zorrilla, S.
  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Sendra, Elena|||0000-0002-4374-2173
  • Zamorano, L.
  • Grau, I.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Morte-Romea, E.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • López Montesinos, I.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Cotarelo, M.|||0000-0002-7017-0369
  • Cantón, R.
  • Oliver, Antonio|||0000-0001-9327-1894
  • Ruiz-Garbajosa, P.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48-72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11-4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37-25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25-4.69), cephalosporins (2.14; 1.35-3.41), and imipenem or meropenem (2.08; 1.03-4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Whole Genome Sequencing Analysis of Klebsiella pneumoniae Isolates from Health Care-Associated Bacteremia of Urinary Origin in Spain, Findings from the Multicenter ITUBRAS-2 Cohort Study

  • Becerra Aparicio, Federico|||0000-0002-0948-0958
  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Hernández García, Marta
  • Xanthopoulou, K.|||0000-0001-8591-8184
  • Gijón, Desiré
  • Siverio Pares, Ana Cristina
  • Berbel, Dàmaris|||0000-0002-3689-3360
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Rivera, Alba|||0000-0002-9709-6162
  • de Malet, A.
  • Xercavins, M.|||0000-0003-1463-6344
  • Ruiz De Gopegui, E.
  • Canoura-Fernández, L.
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Seral, C.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Cotarelo, M.|||0000-0002-7017-0369
  • Ponz, Ricardo|||0009-0007-9027-3326
  • Higgins, P.G.
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, A.
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
  • Ruiz-Garbajosa, P.
  • Montesinos, I.L.
  • Merino, I.
  • de Gopegui, E.R.
  • López-Causapé, C.
  • Grau, I.
  • Sabé, N.
  • Shaw, E.
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Sendra, E.
  • Rubio, V.
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Badía, C.
  • Calvo, E.
  • Fariñas, M.C.
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, M.R.
  • Morte-Romea, E.
  • Paño-Pardo, J.R.
  • Carmona-Torre, F.
  • Quintano, F.T.
  • Sánchez Carrillo, Carlos
  • Cortarelo, M.
Background: The objective of this study was to assess the microbiological and clinical features of Klebsiella pneumoniae health care-associated bacteremia of urinary origin (HCA-BUO) in Spain, with a focus on third-generation cephalosporin-(3GCR-Kp) and carbapenem-resistant K pneumoniae (CR-Kp) isolates. Methods: A total of 96 (21.4%, 96/449) K pneumoniae blood isolates were prospectively collected from patients with HCA-BUO (n = 443) from 12 tertiary care hospitals in Spain (2017-2019). Antimicrobial susceptibility was determined (standard broth microdilution), and extended-spectrum β-lactamase, AmpC, and carbapenemase production was screened. A subset of 55 K pneumoniae isolates was analyzed by whole genome sequencing (Illumina) to determine population structure, resistome, and virulome. Additionally, 13 of these isolates were subjected to long-read sequencing (Nanopore) for plasmid characterization. Patients' baseline and clinical characteristics were reviewed. Results: 3GCR-Kp prevalence was 43.8% (42/96), mostly associated with extended-spectrum β-lactamase production (34/96, 35.4%; mainly CTX-M-15, 32/34, 94.1%) and the dissemination of sequence type (ST)-307 (15/34, 44.1%) and other globally spread multidrug-resistant high-risk clones. CR-Kp prevalence was 9.4% (9/96); all isolates belonged to different STs and were mostly associated with carbapenemase production (6/9, 66.7%; mainly OXA-48-like, n = 3). Additionally, 3GCR-Kp and CR-Kp isolates showed higher content of other antibiotic resistance genes. Altogether, these episodes were associated with prior antibiotic use and receipt of inadequate empirical treatment. Conclusions: There is a high prevalence of 3GCR and CR-Kp causing HCA-BUO in Spain, mainly driven by the dissemination of ST307/CTX-M-15 and other globally spread multidrug-resistant high-risk clones, challenging the selection of empirical and targeted treatments for these infections.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Epidemiological and clinical characterization of community, healthcare-associated and nosocomial colonization and infection due to carbapenemase-producing Klebsiella pneumoniae and Escherichia coli in Spain

  • Palacios-Baena, Z.R.
  • Calvo-Montes, J.
  • Martínez-Martínez, L.
  • Cantón, R.
  • Pitart, Cristina|||0000-0002-3083-7915
  • Bou, German|||0000-0001-8837-0062
  • Pascual, Á.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Alemán, Araceli
  • Rivera, A.
  • Pintado, Vicente
  • Ruiz-Garbajosa, P.
  • Gracia-Ahufinger, I.
  • Quintano, F.T.
  • Clavijo, E.
  • Arias, M.
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Lecuona, M.
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Salamanca-Rivera, Elena
  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Pérez-Vázquez, María
  • Ruiz-Carrascoso, Guillermo
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Mulet, Xavier
  • González-López, Juanjo|||0000-0003-2419-5909
  • Sivianes, Fran
  • Delgado-Valverde, Mercedes
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Canut-Blasco, Andrés
  • Jorge Arribas García
  • Ayestarán, Ignacio
  • Gutiérrez, David
  • Gijón, Desirèe
  • Roca, Ignasi|||0000-0002-1800-1576
  • Nuvials, Xavier|||0000-0002-6648-2394
  • Viñado, Belén|||0000-0001-6212-5886
  • González, Mónica
  • Suberviola Canas, Borja
  • Maria Elicier Cano García
  • Tinajas, Almudena
  • García Bravo, Moises
  • de Tuesta Díaz, Jose Luis
  • Vidal-García, Matxalen
  • Gomáriz Díaz, María
  • Pérez del Molino Bernal, Mª Luisa
  • Coira Nieto, Amparo
  • Rodríguez Tarazona, Raquel Elisa
  • Arenal Andrés, Noelia
  • Paz Vidal, Mª Isabel
  • Rey-Cao, Sonia
  • Martínez Lamas, Lucía
  • Cabezas Fernández, Mª Teresa
  • Cabeza, Mª Isabel
  • Roldán, Carolina
  • Liébana, Carmen
  • Galán Sánchez, Fátima
  • GarcíaSánchez, Federico Juan Manuel
  • Chueca, Natalia|||0000-0002-3420-3290
  • Mora, Laura
  • Martí Salas, Carmina
  • Quesada, Dolores
  • Casabella Pernas, Antonio|||0000-0002-2534-3689
  • Sanchez, Nerea
  • Aldea Mansilla, Carmen
  • Rodríguez Escudero, M. José
  • Huertas, María
  • Gaitán Durán, Jorge
  • Esparcia Rodríguez, Oscar
  • Sainz de Baranda, Caridad
  • Riquelme Bravo, Eva
  • Hernando, Susana
  • Sánchez Arroyo, Rafael
  • Iglesias Nuñez, Nuria
  • Villa, Jennifer
  • Clapés Sanchez, Ester
  • Gimeno, Adelina
  • López Soria, Leyre
  • Barrios Andrés, Jose Luis
  • García Garrote, Fernando
  • Palop, Begoña
  • Valverde Troya, Miriam
  • García-Gonzàlez, Merce
  • Belles, Alba
  • Azcona, José Manuel
  • López-Calleja, Ana Isabel
  • Pérez Moreno, Mar Olga|||0000-0002-4216-4965
  • Fernández Natal, Isabel
  • Garduno Eseverri, Eugenio
  • Sánchez Benito, Rosario
  • de la Iglesia, Pedro
  • Illescas, Soledad
  • Garcia Agudo, Lidia
  • Frasquet, Juan
  • Leiva, José
  • Giner, Salvador
  • López-Urrutia Lorente, Luis
  • Perez Arellano, Jose Luis
  • del Rosario, Cristobal
  • Ortega Lafont, Pilar
  • Martínez Ramírez, Mariela
Background: Community-acquired (CA) and healthcare-associated (HCA) infections caused by carbapenemase-producing Enterobacterales (CPE) are not well characterized. The objective was to provide detailed information about the clinical and molecular epidemiological features of nosocomial, HCA and CA infections caused by carbapenemase-producing Klebsiella pneumoniae (CP-Kp) and Escherichia coli (CP-Ec). Methods: A prospective cohort study was performed in 59 Spanish hospitals from February to March 2019, including the first 10 consecutive patients from whom CP-Kp or CP-Ec were isolated. Patients were stratified according to acquisition type. A multivariate analysis was performed to identify the impact of acquisition type in 30-day mortality. Results: Overall, 386 patients were included (363 [94%] with CP-Kp and 23 [6%] CP-Ec); in 296 patients (76.3%), the CPE was causing an infection. Acquisition was CA in 31 (8.0%) patients, HCA in 183 (47.4%) and nosocomial in 172 (48.3%). Among patients with a HCA acquisition, 100 (54.6%) had been previously admitted to hospital and 71 (38.8%) were nursing home residents. Urinary tract infections accounted for 19/23 (82.6%), 89/130 (68.5%) and 42/143 (29.4%) of CA, HCA and nosocomial infections, respectively. Overall, 68 infections (23%) were bacteremia (8.7%, 17.7% and 30.1% of CA, HCA and nosocomial, respectively). Mortality in infections was 28% (13%, 14.6% and 42.7% of CA, HCA and nosocomial, respectively). Nosocomial bloodstream infections were associated with increased odds for mortality (adjusted OR, 4.00; 95%CI 1.21-13.19). Conclusions: HCA and CA infections caused by CPE are frequent and clinically significant. This information may be useful for a better understanding of the epidemiology of CPE.
RODIN. Repositorio de Objetos de Docencia e Investigación de la Universidad de Cádiz
Publicación Artículo científico (JournalArticle)

Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project

  • Mussa, Marco
  • Martínez Pérez-Crespo, Pedro María
  • Lopez Cortes, Luis Eduardo
  • Retamar Gentil, Pilar
  • Sousa Dominguez, Adrián
  • Goikoetxea Aguirre, Ane Josune
  • Reguera Iglesias, José María
  • León Jiménez, Eva
  • Fernández Natal, Isabel
  • Armiñanzas Castillo, Carlos
  • Boix Palop, Lucía
  • Cuquet Pedragosa, Jordi
  • Morán Rodríguez, Miguel Ángel
  • Fernandez Suarez, Jonathan
  • del Arco Jiménez, Alfonso
  • Jóver Saenz, Alfredo
  • Bahamonde Carrasco, Alberto
  • Galán Sánchez, Fátima
  • Sánchez Calvo, Juan Manuel
  • Smithson Amat, Alejandro
  • Vinuesa García, David
  • Sánchez Porto, Antonio
  • López Hernández, Inmaculada
  • Rodríguez Baño, Jesús
  • Lanz García, Joaquín
  • Montejo, Miguel
  • Pérez Rodríguez, María Teresa
  • Corzo Delgado, Enrique
  • Fariñas, Carmen
  • Arias Temprano, Marta
  • Martín Aspas, Andrés
  • Gea Lázaro, Isabel
  • Guzmán García, Marcos
  • Canueto Quintero, Jesús
  • Reche, Isabel María
  • Pérez Camacho, Inés
  • Merino de Lucas, Esperanza
  • Natera Kindelán, Clara
Biliary-tract bloodstream infections (BT-BSI) caused by Enterococcus faecalis and E. faecium are associated with inappropriate empirical treatment and worse outcomes compared to other etiologies. The objective of this study was to investigate the risk factors for enterococcal BT-BSI. Patients with BT-BSI from the PROBAC cohort, including consecutive patients with BSI in 26 Spanish hospitals between October 2016 and March 2017, were selected; episodes caused by E. faecalis or E. faecium and other causes were compared. Independent predictors for enterococci were identified by logistic regression, and a predictive score was developed. Eight hundred fifty episodes of BT-BSI were included; 73 (8.5%) were due to target Enterococcus spp. (48 [66%] were E. faecium and 25 [34%] E. faecalis). By multivariate analysis, the variables independently associated with Enterococcus spp. were (OR; 95% confidence interval): cholangiocarcinoma (4.48;1.32 to 15.25), hospital acquisition (3.58;2.11 to 6.07), use of carbapenems in the previous month (3.35;1.45 to 7.78), biliary prosthesis (2.19;1.24 to 3.90), and moderate or severe chronic kidney disease (1.55;1.07 to 2.26). The AUC of the model was 0.74 [95% CI0.67 to 0.80]. A score was developed, with 7, 6, 5, 4, and 2 points for these variables, respectively, with a negative predictive value of 95% for a score # 6. A model, including cholangiocarcinoma, biliary prosthesis, hospital acquisition, previous carbapenems, and chronic kidney disease showed moderate prediction ability for enterococcal BT-BSI. Although the score will need to be validated, this information may be useful for deciding empirical therapy in biliary tract infections when bacteremia is suspected. IMPORTANCE Biliary tract infections are frequent, and a significant cause of morbidity and mortality. Bacteremia is common in these infections, particularly in the elderly and patients with cancer. Inappropriate empirical treatment has been associated with increased risk of mortality in bacteremic cholangitis, and the probability of receiving inactive empirical treatment is higher in episodes caused by enterococci. This is because many of the antimicrobial agents recommended in guidelines for biliary tract infections lack activity against these organisms. To the best of our knowledge, this is the first study analyzing the predictive factors for enterococcal BT-BSI and deriving a predictive score., 8 páginas
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Distinct epidemiology and resistance mechanisms affecting ceftolozane/tazobactam in Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal depicted by WGS

  • Hernández-García, Marta
  • García-Castillo, María
  • García-Fernández, Sergio
  • Melo-Cristino, José
  • Pinto, Margarida Feijó
  • Gonçalves, Elsa
  • Alves, Valquíria
  • Vieira, Ana Raquel
  • Ramalheira, Elmano
  • Sancho, Luísa
  • Diogo, José
  • Ferreira, Rui
  • Silva, Tania
  • Chaves, Catarina
  • Bou, Germán
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Oliver, Antonio
  • Pitart, Cristina
  • Rodríguez-Lozano, Jesús
  • Tormo, Nuria
  • Romano, Joao
  • Pássaro, Leonor
  • Paixao, Laura
  • López-Mendoza, Diego
  • Díaz-Regañón, Jazmín
  • Cantón, Rafael
[Abstract] Objectives: To analyse the epidemiology, the resistome and the virulome of ceftolozane/tazobactam-susceptible or -resistant Pseudomonas aeruginosa clinical isolates recovered from surveillance studies in Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17). Methods: P. aeruginosa isolates were recovered from intra-abdominal, urinary tract and lower respiratory tract infections in ICU patients admitted to 11 Portuguese and 8 Spanish hospitals. MICs were determined (ISO-standard broth microdilution, EUCAST 2020 breakpoints). A subset of 28 ceftolozane/tazobactam-resistant P. aeruginosa isolates were analysed and compared with 28 ceftolozane/tazobactam-susceptible P. aeruginosa strains by WGS. Results: Clonal complex (CC) 235 (27%) and CC175 (18%) were the most frequent, followed by CC244 (13%), CC348 (9%), CC253 (5%) and CC309 (5%). Inter-hospital clonal dissemination was observed, limited to a geographical region (CC235, CC244, CC348 and CC253 in Portugal and CC175 and CC309 in Spain). Carbapenemases were detected in 25 isolates (45%): GES-13 (13/25); VIM type (10/25) [VIM-2 (4/10), VIM-20 (3/10), VIM-1 (2/10) and VIM-36 (1/10)]; and KPC-3 (2/25). GES-13-CC235 (13/15) and VIM type-CC175 (5/10) associations were observed. Interestingly, KPC-3 and VIM-36 producers showed ceftolozane/tazobactam-susceptible phenotypes. However, ceftolozane/tazobactam resistance was significantly associated with GES-13 and VIM-type carbapenemase production. Six non-carbapenemase producers also displayed ceftolozane/tazobactam resistance, three of them showing known ceftolozane/tazobactam resistance-associated mutations in the PBP3 gene, ftsI (R504C and F533L). Overall, an extensive virulome was identified in all P. aeruginosa isolates, particularly in carbapenemase-producing strains. Conclusions: GES-13-CC235 and VIM type-CC175 were the most frequent MDR/XDR P. aeruginosa clones causing infections in Portuguese and Spanish ICU patients, respectively. Ceftolozane/tazobactam resistance was mainly due to carbapenemase production, although mutations in PBP-encoding genes may additionally be involved., The study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I + D + i 2013–16 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases [RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011], co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (EDRF), Operative Program Intelligent Growth 2014–20. M.H.-G. is supported by a research contract from a European Project [IMI-JU-9–2013, Ref. iABC - 115721–2].
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vitro activity of Cefepime-Taniborbactam against Carbapenemase-producing Enterobacterales and Pseudomonas aeruginosa isolates recovered in Spain

  • Hernández-García, Marta
  • García-Castillo, María
  • Ruiz-Garbajosa, Patricia
  • Bou, Germán
  • Siller, María
  • Pitart, Cristina
  • Gracia-Ahufinger, Irene
  • Mulet, Xavier
  • Pascual, Álvaro
  • Tormo, Nuria
  • Cantón, Rafael
[Abstract] Novel β-lactam-β-lactamase inhibitor combinations currently approved for clinical use are poorly active against metallo-β-lactamase (MBL)-producing strains. We evaluated the in vitro activity of cefepime-taniborbactam (FTB [formerly cefepime-VNRX-5133]) and comparator agents against carbapenemase-producing Enterobacterales (n = 247) and carbapenem-resistant Pseudomonas species (n = 170) clinical isolates prospectively collected from different clinical origins in patients admitted to 8 Spanish hospitals. FTB was the most active agent in both Enterobacterales (97.6% MICFTB, ≤8/4 mg/L) and Pseudomonas (67.1% MICFTB, ≤8/4 mg/L) populations. The MICFTB was >8 mg/L in 6/247 (2.4%) Enterobacterales isolates (3 KPC-producing Klebsiella pneumoniae isolates, 1 VIM-producing Enterobacter cloacae isolate, 1 IMP-producing E. cloacae isolate, and 1 NDM-producing Escherichia coli isolate) and in 56/170 (32.9%) Pseudomonas isolates, 19 of them carbapenemase producers (15 producers of VIM, 2 of GES, 1 of GES+VIM, and 1 of GES+KPC). Against the Enterobacterales isolates with meropenem MICs of >2 mg/L (138/247), FTB was the most active agent against both serine-β-lactamases (107/138) and MBL producers (31/138) (97.2 and 93.5% MICFTB, ≤8/4 mg/L, respectively), whereas the activity of comparators was reduced, particularly against the MBL producers (ceftazidime-avibactam, 94.4 and 12.9%, meropenem-vaborbactam, 85.0 and 64.5%, imipenem-relebactam, 76.6 and 9.7%, ceftolozane-tazobactam, 1.9 and 0%, and piperacillin-tazobactam, 0 and 0%, respectively). Among the meropenem-resistant Pseudomonas isolates (163/170; MIC, >2 mg/L), the activities of FTB against serine-β-lactamase (35/163) and MBL (43/163) producers were 88.6 and 65.1%, respectively, whereas the susceptibilities of comparators were as follows: ceftazidime-avibactam, 88.5 and 16.0%, meropenem-vaborbactam, 8.5 and 7.0%, imipenem-relebactam, 2.9 and 2.3%, ceftolozane-tazobactam, 0 and 2.3%, and piperacillin-tazobactam, 0 and 0%, respectively. Microbiological results suggest FTB as a potential therapeutic option in patients infected with carbapenemase-producing Enterobacterales and carbapenem-resistant Pseudomonas isolates, including MBL producers., This project was sponsored by Venatorx Pharmaceuticals and has been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under contract no. HHSO100201900007C. This study was also supported by Plan Nacional de I+D + i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0008, RD16/0016/0010, and REIPI RD16/0016/0011), cofinanced by the European Development Regional Fund “A Way to Achieve Europe” (ERDF), operative program Intelligent Growth 2014–2020 and CIBER en Enfermedades Infecciosas (CIBERINF) (CB21/13/00084).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vitro activity of imipenem/relebactam against Pseudomonas aeruginosa isolates recovered from ICU patients in Spain and Portugal (SUPERIOR and STEP studies)

  • Hernández-García, Marta
  • García-Castillo, María
  • Melo-Cristino, José
  • Pinto, Margarida Feijó
  • Gonçalves, Elsa
  • Alves, Valquíria
  • Vieira, Ana Raquel
  • Ramalheira, Elmano
  • Sancho, Luísa
  • Diogo, José
  • Ferreira, Rui
  • Cruz, Hugo
  • Chaves, Catarina
  • Bou, Germán
  • Cercenado, Emilia
  • Delgado-Valverde, Mercedes
  • Oliver, Antonio
  • Pitart, Cristina
  • Rodríguez-Lozano, Jesús
  • Tormo, Nuria
  • Díaz-Regañón, Jazmín
  • Pássaro, Leonor
  • Duarte, Joana
  • Cantón, Rafael
[Abstract] Objectives: To study the in vitro activity of imipenem/relebactam and comparators and the imipenem/relebactam resistance mechanisms in a Pseudomonas aeruginosa collection from Portugal (STEP, 2017-18) and Spain (SUPERIOR, 2016-17) surveillance studies. Methods: P. aeruginosa isolates (n = 474) were prospectively recovered from complicated urinary tract (cUTI), complicated intra-abdominal (cIAI) and lower respiratory tract (LRTI) infections in 11 Portuguese and 8 Spanish ICUs. MICs were determined (ISO broth microdilution). All imipenem/relebactam-resistant P. aeruginosa isolates (n = 30) and a subset of imipenem/relebactam-susceptible strains (n = 32) were characterized by WGS. Results: Imipenem/relebactam (93.7% susceptible), ceftazidime/avibactam (93.5% susceptible) and ceftolozane/tazobactam (93.2% susceptible) displayed comparable activity. The imipenem/relebactam resistance rate was 6.3% (Portugal 5.8%; Spain 8.9%). Relebactam restored imipenem susceptibility to 76.9% (103/134) of imipenem-resistant isolates, including MDR (82.1%; 32/39), XDR (68.8%; 53/77) and difficult-to-treat (DTR) isolates (67.2%; 45/67). Among sequenced strains, differences in population structure were detected depending on the country: clonal complex (CC)175 and CC309 in Spain and CC235, CC244, CC348 and CC253 in Portugal. Different carbapenemase gene distributions were also found: VIM-20 (n = 3), VIM-1 (n = 2), VIM-2 (n = 1) and VIM-36 (n = 1) in Spain and GES-13 (n = 13), VIM-2 (n = 3) and KPC-3 (n = 2) in Portugal. GES-13-CC235 (n = 13) and VIM type-CC175 (n = 5) associations were predominant in Portugal and Spain, respectively. Imipenem/relebactam showed activity against KPC-3 strains (2/2), but was inactive against all GES-13 producers and most of the VIM producers (8/10). Mutations in genes affecting porin inactivation, efflux pump overexpression and LPS modification might also be involved in imipenem/relebactam resistance. Conclusions: Microbiological results reinforce imipenem/relebactam as a potential option to treat cUTI, cIAI and LRTI caused by MDR/XDR P. aeruginosa isolates, except for GES-13 and VIM producers., The study was funded by MSD Portugal (protocol VP6918) and MSD Spain (protocol MSD-CEF-2016-01). This study was also supported by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Economía, Industria y Competitividad, Spanish Network for Research in Infectious Diseases (RD16/0016/0001, RD16/0016/0004, RD16/0016/0006, RD16/0016/0007, RD16/0016/0010 and REIPI RD16/0016/0011), co-financed by the European Development Regional Fund ‘A way to achieve Europe’ (ERDF), Operative program Intelligent Growth 2014–2020 and CIBER de Enfermedades Infecciosas (CIBERINFEC) (CB21/13/00084), Instituto de Salud Carlos III, Madrid, Spain.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Risk Factors and Predictive Score for Bacteremic Biliary Tract Infections Due to Enterococcus faecalis and Enterococcus faecium: a Multicenter Cohort Study from the PROBAC Project

  • Mussa, Marco
  • Martínez Pérez-Crespo, Pedro María
  • López-Cortés, Luis Eduardo
  • Retamar Gentil, Pilar
  • Sousa, Adrián
  • Goikoetxea-Aguirre, Josune
  • Reguera Iglesias, José María
  • León Jiménez, Eva
  • Fernández-Natal, Isabel
  • Armiñanzas Castillo, Carlos
  • Boix-Palop, Lucía
  • Cuquet Pedragosa, Jordi
  • Morán Rodríguez, Miguel Ángel
  • Fernández Suárez, Jonathan
  • Arco-Jiménez, Alfonso del
  • Jover-Sáenz, Alfredo
  • Bahamonde-Carrasco, Alberto
  • Galán-Sánchez, Fátima
  • Sánchez Calvo, Juan Manuel
  • Smithson Amat, Alejandro
  • Vinuesa García, David
  • Sánchez-Porto, Antonio
  • López-Hernández, Inmaculada
  • Rodríguez-Baño, Jesús
Biliary-tract bloodstream infections (BT-BSI) caused by Enterococcus faecalis and E. faecium are associated with inappropriate empirical treatment and worse outcomes compared to other etiologies. The objective of this study was to investigate the risk factors for enterococcal BT-BSI. Patients with BT-BSI from the PROBAC cohort, including consecutive patients with BSI in 26 Spanish hospitals between October 2016 and March 2017, were selected; episodes caused by E. faecalis or E. faecium and other causes were compared. Independent predictors for enterococci were identified by logistic regression, and a predictive score was developed. Eight hundred fifty episodes of BT-BSI were included; 73 (8.5%) were due to target Enterococcus spp. (48 [66%] were E. faecium and 25 [34%] E. faecalis). By multivariate analysis, the variables independently associated with Enterococcus spp. were (OR; 95% confidence interval): cholangiocarcinoma (4.48;1.32 to 15.25), hospital acquisition (3.58;2.11 to 6.07), use of carbapenems in the previous month (3.35;1.45 to 7.78), biliary prosthesis (2.19;1.24 to 3.90), and moderate or severe chronic kidney disease (1.55;1.07 to 2.26). The AUC of the model was 0.74 [95% CI0.67 to 0.80]. A score was developed, with 7, 6, 5, 4, and 2 points for these variables, respectively, with a negative predictive value of 95% for a score ≤ 6. A model, including cholangiocarcinoma, biliary prosthesis, hospital acquisition, previous carbapenems, and chronic kidney disease showed moderate prediction ability for enterococcal BT-BSI. Although the score will need to be validated, this information may be useful for deciding empirical therapy in biliary tract infections when bacteremia is suspected. IMPORTANCE Biliary tract infections are frequent, and a significant cause of morbidity and mortality. Bacteremia is common in these infections, particularly in the elderly and patients with cancer. Inappropriate empirical treatment has been associated with increased risk of mortality in bacteremic cholangitis, and the probability of receiving inactive empirical treatment is higher in episodes caused by enterococci. This is because many of the antimicrobial agents recommended in guidelines for biliary tract infections lack activity against these organisms. To the best of our knowledge, this is the first study analyzing the predictive factors for enterococcal BT-BSI and deriving a predictive score., This work was financed by Plan Nacional de I+D+i 2013‐2016, Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades, through grants PI16/01432 and Spanish Network for Research in Infectious Diseases (REIPI) [RD16/0016/0001; RD16/0016/0007; and RD16/0016/0012]; co‐financed by European Development Regional Fund “A Way to Achieve Europe,” Operative program Intelligent Growth 2014–2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Risk of cardiac device-related infection in patients with late-onset bloodstream infection. Analysis on a National Cohort

  • Boix-Palop, Lucía
  • Dietl, Beatriz
  • Calbo, Esther
  • Di Marco, Andrea
  • Xercavins, Mariona
  • Martínez Pérez-Crespo, Pedro María
  • Sousa, Adrián
  • Montejo, Miguel
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] To determine the incidence of cardiac device-related infection (CDRI) among patients with cardiac device (CD) during late-onset bloodstream infection (BSI) and to identify the risk factors associated with CDRI., [Methods] Patients with a CD (cardiac implantable electronic devices -CIED- and/or prosthetic heart valve -PHV-) and late-onset-BSI (>1 year after the CD implantation/last manipulation) were selected from the PROBAC project, a prospective, observational cohort study including adult patients with bacteraemia consecutively admitted to 26 Spanish hospitals from October 2016 to March 2017. Multivariate analyses using logistic regression were performed to identify the risk factors associated with CDRI., [Results] 317 BSI from patients carrying a CD were registered, 187 (56.2%) were late-onset-BSI. A total of 40 (21.4%) CDRI were identified during late-onset-BSI. The CDRI cumulative incidence in Gram-positive-BSI was 41.8% (38/91), with S. aureus, Enterococcus spp. and viridans streptococci showing the greatest percentages: 40% (12/30), 42% (11/26) and 75% (6/8), respectively. Independent predictors of CDRI were an unknown source of infection (OR: 2.88 [CI 95%:1.18–7.06], p = 0.02), Gram-positive-aetiology (23.1 [5.23–102.1], p < 0.001) and persistent bacteraemia (4.81 [1.21–19], p = 0.03). In an exploratory analysis, S. aureus (3.99 [1.37–11.65], p = 0.011), Enterococcus spp. (5.21 [1.76–15.4], p = 0.003) and viridans streptococci (28.7 [4.71–173.5], p < 0.001) aetiology were also found to be risk factors for CDRI., [Conclusions] CDRI during late-onset-BSI is a frequent phenomenon. Risk of CDRI differs among species, happening in almost half of the Gram-positive-BSI. An unknown source of the primary infection, Gram-positive-aetiology -especially S. aureus, Enterococcus spp. and viridans streptococci-, and persistent bacteraemia were identified as risk factors for CDRI., This study was funded by Plan Nacional de I+D+i 2013–2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, through the following grants: Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; RD16/0016/0007; RD16/0016/0008; RD16/0016/0012), co-financed by European Development Regional Fund ‘A way to achieve Europe’, Operative Program Intelligent Growth 2014–2020, and PI16/01432., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Effectiveness of oral step-down therapy and early oral switch for bloodstream infections caused by Enterobacterales: A post hoc emulation trial of the SIMPLIFY trial

  • Rando, Emanuele
  • Delgado-Valverde, Mercedes
  • Goikoetxea-Aguirre, Josune
  • Guio Carrión, Laura
  • Blanco-Vidal, María José
  • Barrios Andrés, José Luis
  • Pérez-Rodríguez, María Teresa
  • Martínez-Lamas, Lucía
  • Arnaiz de Las Revillas, Francisco
  • Armiñanzas, Carlos
  • Ruiz de Alegría, Carlos
  • Jiménez-Aguilar, Patricia
  • Martínez-Rubio, María del Carmen
  • Sáez-Béjar, Carmen
  • Cuevas, Carmen de las
  • Martín-Aspas, Andrés
  • Galán, Fátima
  • Yuste, José Ramón
  • Leiva-León, José
  • Bou, Germán
  • Capón González, Patricia
  • Boix-Palop, Lucía
  • Xercavins-Valls, Mariona
  • Goenaga Sánchez, Miguel Ángel
  • Anza, Diego Vicente
  • Castón, Juan José
  • Recio Rufián, Manuel
  • Merino, Esperanza
  • Rodríguez, Juan Carlos
  • Loeches, Belén
  • Rosso-Fernández, Clara
  • Bravo-Ferrer, José María
  • Retamar-Gentil, Pilar
  • Rodríguez-Baño, Jesús
  • López-Cortés, Luis Eduardo
[Objectives] We investigated the effectiveness of early oral switch for treating Enterobacterales bloodstream infection (BSI) by performing a post hoc emulation trial of the SIMPLIFY trial., [Methods] We conducted a post hoc analysis of a randomized controlled trial. We specified the target trial characteristics selecting patients who achieved clinical stability on day 5. We categorized patients into those who switched on day 5 and those who continued intravenously. The primary outcome was clinical cure at the test of cure. We set a propensity score for being switched on day 5 to reduce confounding. We ran simple, not-propensity-adjusted, and propensity-adjusted logistic regression models to ascertain the association of switch on day 5 with clinical cure., [Results] Among 303 patients who achieved clinical stability on day 5, 110 (36.3%) were switched orally on day 5, and 193 (63.7%) were kept intravenously. We detected no difference in clinical cure between those switched on day 5 and those continued intravenously (risk ratios 1.04, 95% confidence intervals [CI] 0.98-1.10). Propensity-adjusted analysis did not show an association between day 5 switch and clinical cure (OR 2.10, 95% CI 0.96-7.41)., [Conclusion] Oral step-down therapy on day 5 was not associated with worse clinical cure for Enterobacterales BSI., The study was funded by the Plan Nacional de I+D+i 2013‐2016 and Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0001; 0002; 0003; 0005; 0007; 0008; 0009; 0011; 0012; 0015); Spanish Clinical Research and Clinical Trials Platform, (SCReN, PT13/0002/0010 and PT17/0017/0012, and PI15/00439), co‐financed by European Union; European Development Regional Fund “A way to achieve Europe,” Operative Program Intelligence Growth 2014‐2020., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fosfomycin in bacteraemic urinary tract infection due to multidrug-resistant Escherichia coli: insights of post hoc DOOR analysis of the FOREST trial

  • Sojo-Dorado, Jesús
  • López-Hernández, Inmaculada
  • Gutiérrez-Gutiérrez, Belén
  • Rosa-Riestra, Sandra de la
  • Docobo-Pérez, Fernando
  • Hernánez-Torres, Alicia
  • Pascual, Álvaro
  • Rodríguez-Baño, Jesús
[Purpose] A post hoc analysis of data from a previously published clinical trial was conducted using the desirability of outcome ranking (DOOR) methodology with the aim provide additional information on the use of fosfomycin for the treatment of bacteraemic urinary tract infection (BUTI) caused by multi-drug-resistant (MDR) E. coli., [Methods] Three DOOR systems with five, six and seven categories, respectively were developed. Safety and efficacy were prioritised in all rankings, but step down to oral therapy and exposure to antibiotics with lower ecological impact were also considered in DOOR-6 and DOOR-7. The probability that a patients assigned to fosfomycin was classified into a more desirable outcome category was calculated for the three DOOR definitions. Subgroups analyses and an ordinal logistic regression model were also performed., [Results] Data from 143 participants were analysed. The probability of having a more desirable outcome after treatment with fosfomycin versus the comparators was 0.44 (95% CI 0.36 − 0.52) for DOOR-5; 0.50 (95% IC 0.42 − 0.58) using DOOR-6 and 0.61 (95% CI 0.53–0.69) with DOOR-7. In subgroups, the highest probability of having a better DOOR with fosfomycin was seen in the clinically evaluable population and among patients without chronic heart disease or renal insufficiency for the DOOR-7 definition., [Conclusions] DOOR analysis could be applied to the FOREST trial data; the results were somehow different for the different DOOR systems used. Overall, fosfomycin was favoured when oral step-down treatment and use of antibiotics with lower ecological impact were included., The study was funded by grants RD16/0016/0001, 0002, 0003, 0005, 0007, 0008, 0009, 0011, 0012, and 0015 from Plan Nacional de Investigación, Desarrollo e Innovación (I + D + i) 2013 to 2016 and the Instituto de Salud Carlos III, Subdirección General de Redes y Centros de Investigación Cooperativa, Ministerio de Ciencia, Innovación y Universidades, Spanish Network for Research in Infectious Diseases (REIPI); PT13/0002/0010 and PT17/0017/0012 from the Spanish Clinical Research and Clinical Trials Platform (SCReN); and PI 13/01282 co-financed by the European Development Regional Fund “A Way to Achieve Europe” and Operative Program Intelligence Growth 2014 to 2020. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance: Even Worse than Hospital Acquired Infections?

  • Gómez-Zorrilla, Silvia
  • Becerra-Aparicio, Federico
  • López Montesinos, Inmaculada
  • Ruiz de Gopegui, Enrique
  • Grau, Inmaculada
  • Pintado, Vicente
  • Padilla, Belén
  • Benito, Natividad
  • Boix-Palop, Lucía
  • Fariñas, Maria Carmen
  • Peñaranda, María
  • Gamallo, Maria Rocío
  • Martinez, Jose Antonio
  • Morte-Romea, Elena
  • Del Pozo, Jose Luis
  • Durán-Jordá, Xavier
  • Díaz-Regañón, Jazmin
  • López-Mendoza, Diego
  • Cantón, Rafael
  • Oliver, Antonio
  • Ruiz-Garbajosa, Patricia
  • Horcajada, Juan Pablo
  • Siverio, Ana
  • Gijón, Desiré
  • Merino, Irene
  • López-Causapé, Carla
  • Sabé, Nuria
  • Shaw, Evelyn
  • Berbel, Dámaris
  • Tubau Quintano, Fe
  • Sánchez Carrillo, Carlos
  • Cercenado, Emilia
  • Sendra, Elena
  • Rubio, Verónica
  • Rivera, Alba
  • Calvo, Esther
  • Badía, Cristina
  • Xercavins, Mariona
  • de Malet, Ana
  • Canoura-Fernández, Luis
  • Salvo, Soledad
  • Paño-Pardo, Jose Ramón
  • Carmona-Torre, Francisco
Introduction: Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. Methods: ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Results: Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77–6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27–6.44) and Charlson index (aOR 1.11; 95% CI 1.01–1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40–0.93) were less likely to present clinical cure. Conclusion: The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. © 2021, The Author(s).
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Risk factors and clinical impact of multi drug resistance in healthcare-associated bacteremic urinary tract infections: a post-hoc analysis of a multi center prospective cohort in Spain

  • Gómez Zorrilla, S.
  • Becerra Aparicio, F.
  • Sendra, E.
  • Zamorano, L.
  • Grau, I.
  • Pintado, V.
  • Padilla, B.
  • Benito, N.
  • Boix Palop, L
  • Fariñas, M.C.
  • Peñaranda, M.
  • Gamallo, M.R.
  • Martínez, J.A.
  • Morte Romea, E.
  • Del Pozo, J.L.
  • López Montesinos, I.
  • Durán Jordá, X.
  • Ponz, R.
  • Cotarelo, M.
  • Cantón, R.
  • Oliver, A.
  • Ruiz Garbajosa, P.
  • Horcajada, J.P.
Background: The global burden associated with antimicrobial resistance is of increasing concern. Aim: To evaluate risk factors associated with multidrug-resistant (MDR) infection and its clinical impact in a cohort of patients with healthcare-associated bacteraemic urinary tract infections (BUTIs). Methods: This was a prospective, multicentre, post-hoc analysis of patients with healthcare-associated-BUTI (ITUBRAS-2). The primary outcome was MDR profile. Secondary outcomes were clinical response (at 48–72 h and at hospital discharge) and length of hospital stay from onset of BUTI. Logistic regression was used to evaluate variables associated with MDR profile and clinical response. Length of hospital stay was evaluated using multivariate median regression. Findings: In all, 443 episodes were included, of which 271 (61.17%) were classified as expressing an MDR profile. In univariate analysis, MDR profile was associated with E. coli episodes (odds ratio (OR): 3.13; 95% confidence interval (CI): 2.11–4.69, P < 0.001) and the extensively drug-resistant (XDR) pattern with P. aeruginosa aetiology (7.84; 2.37–25.95; P = 0.001). MDR was independently associated with prior use of fluoroquinolones (adjusted OR: 2.43; 95% CI: 1.25–4.69), cephalosporins (2.14; 1.35–3.41), and imipenem or meropenem (2.08; 1.03–4.20) but not with prior ertapenem. In terms of outcomes, MDR profile was not associated with lower frequency of clinical cure, but was associated with longer hospital stay. Conclusion: MDR profile was independently associated with prior use of fluoroquinolones, cephalosporins, imipenem, and meropenem, but not with prior ertapenem. MDR-BUTI episodes were not associated with worse clinical cure, although they were independently associated with longer duration of hospital stay.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A Large Multicenter Prospective Study of Community-Onset Healthcare Associated Bacteremic Urinary Tract Infections in the Era of Multidrug Resistance, Even Worse than Hospital Acquired Infections?

  • Gómez-Zorrilla, Silvia|||0000-0002-5987-068X
  • Becerra-Aparicio, Federico
  • López Montesinos, Inmaculada|||0000-0002-2675-4412
  • Ruiz de Gopegui, Enrique
  • Grau, Inmaculada
  • Pintado, Vicente
  • Padilla Ortega, Belén
  • Benito, Natividad|||0000-0001-6410-013X
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Fariñas, Mª Carmen
  • Peñaranda, María|||0000-0001-6290-3457
  • Gamallo, Maria Rocío
  • Martinez Martinez, Jose Antonio|||0000-0002-7012-9817
  • Morte-Romea, Elena
  • Del Pozo, Jose Luis|||0000-0002-5402-3334
  • Duran-Jordà, Xavier|||0000-0001-8517-9254
  • Díaz-Regañón, Jazmin
  • López-Mendoza, Diego
  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Ruiz-Garbajosa, Patricia
  • Horcajada, Juan Pablo|||0000-0001-9873-5459
Healthcare-associated (HCA) infections represent a growing public health problem. The aim of this study was to compare community-onset healthcare associated (CO-HCA) bacteremic urinary tract infections (BUTI) and hospital-acquired (HA)-BUTI with special focus on multidrug resistances (MDR) and outcomes. ITUBRAS-project is a prospective multicenter cohort study of patients with HCA-BUTI. All consecutive hospitalized adult patients with CO-HCA-BUTI or HA-BUTI episode were included in the study. Exclusion criteria were: patients < 18 years old, non-hospitalized patients, bacteremia from another source or primary bacteremia, non-healthcare-related infections and infections caused by unusual pathogens of the urinary tract. The main outcome variable was 30-day all-cause mortality with day 1 as the first day of positive blood culture. Logistic regression was used to analyze factors associated with clinical cure at hospital discharge and with receiving inappropriate initial antibiotic treatment. Cox regression was used to evaluate 30-day all-cause mortality. Four hundred forty-three episodes were included, 223 CO-HCA-BUTI. Patients with CO-HCA-BUTI were older (p < 0.001) and had more underlying diseases (p = 0.029) than those with HA-BUTI. The severity of the acute illness (Pitt score) was also higher in CO-HCA-BUTI (p = 0.026). Overall, a very high rate of MDR profiles (271/443, 61.2%) was observed, with no statistical differences between groups. In multivariable analysis, inadequate empirical treatment was associated with MDR profile (aOR 3.35; 95% CI 1.77-6.35), Pseudomonas aeruginosa (aOR 2.86; 95% CI 1.27-6.44) and Charlson index (aOR 1.11; 95% CI 1.01-1.23). Mortality was not associated with the site of acquisition of the infection or the presence of MDR profile. However, in the logistic regression analyses patients with CO-HCA-BUTI (aOR 0.61; 95% CI 0.40-0.93) were less likely to present clinical cure. The rate of MDR infections was worryingly high in our study. No differences in MDR rates were found between CO-HCA-BUTI and HA-BUTI, in the probability of receiving inappropriate empirical treatment or in 30-day mortality. However, CO-HCA-BUTIs were associated with worse clinical cure. The online version contains supplementary material available at 10.1007/s40121-021-00537-0.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Comparison of light capturing approaches in Laser-Induced Breakdown Spectroscopy (LIBS) for multichannel spectrometers

  • Fernández-Manteca, María Gabriela|||0000-0002-7605-5409
  • Martínez-Minchero, Marina
  • García Escárzaga, Asier|||0000-0002-3625-0824
  • Ocampo-Sosa, Alain A.|||0000-0002-9104-3115
  • Mirapeix, Jesús|||0000-0002-6035-0139
  • Valdiande, José J.
  • López-Higuera, José Miguel|||0000-0002-8615-8487
  • Rodríguez-Cobo, Luis|||0000-0002-2068-2956
  • Cobo, Adolfo|||0000-0003-1498-9238
LIBS technique requires the spectroscopic analysis of the light emitted by a laser-induced plasma plume. One challenge of the different approaches to capture the plasma light emission is the significant shot-to-shot variations of the plume inhomogeneities, position, and morphology. This is even more challenging when multichannel CCD spectrometers are used, because the light should be homogeneously divided among multiple capturing optical fibers (typically up to 8 fibers) with stable spectral efficiency for all channels. Otherwise, any further analysis of the atomic emission spectra involving multiple channels, such as line intensity ratios, Boltzmann plots, or calibration-free LIBS, could be compromised by the morphology-dependent spectral artifacts induced by the collection optics. In this work, we assess the performance of several collection optics in terms of overall capturing efficiency and channel-to-channel variations due to changes in plasma morphology. Results clearly show that this could be an issue even with the approaches with the best spatial homogenization, including optical fibers and Köhler optics.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

CARB-ES-19 Multicenter Study of Carbapenemase-Producing Klebsiella pneumoniae and Escherichia coli From All Spanish Provinces Reveals Interregional Spread of High-Risk Clones Such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual Hernández, Álvaro|||0000-0002-8672-5891
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
Objectives: CARB-ES-19 is a comprehensive, multicenter, nationwide study integrating whole-genome sequencing (WGS) in the surveillance of carbapenemase-producing K. pneumoniae (CP-Kpn) and E. coli (CP-Eco) to determine their incidence, geographical distribution, phylogeny, and resistance mechanisms in Spain. Methods: In total, 71 hospitals, representing all 50 Spanish provinces, collected the first 10 isolates per hospital (February to May 2019); CPE isolates were first identified according to EUCAST (meropenem MIC.
Dipòsit Digital de Documents de la UAB
Publicación Artículo de revisión (ReviewArticle)

Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems, Recomendaciones del Comité Español del Antibiograma (COESANT) para la selección de antimicrobianos y sus concentraciones en el estudio in vitro de la sensibilidad con métodos automáticos

  • Cantón, Rafael|||0000-0003-1675-3173
  • Oliver, Antonio|||0000-0001-9327-1894
  • Alós, Juan Ignacio
  • Benito, Natividad|||0000-0001-6410-013X
  • Bou, German|||0000-0001-8837-0062
  • Campos, José
  • Calvo, Jorge
  • Canut-Blasco, Andrés
  • Castillo, Javier
  • Cercenado, Emilia|||0000-0002-5279-3773
  • Domínguez, Maria Ángeles
  • Fernández-Cuenca, Felipe
  • Guinea, Jesús
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Liñares, Josefina
  • López-Cerero, Lorena
  • López-Navas, Antonio
  • Marco, Francesc|||0000-0002-1863-6379
  • Mirelis, Beatriz
  • Moreno-Romo, Miguel Ángel
  • Morosini, María Isabel
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
  • Pascual Leone, Álvaro|||0000-0001-8975-0382
  • Pérez Trallero, Emilio
  • Pérez-Vázquez, María
  • Soriano Viladomiu, Alex|||0000-0002-9374-0811
  • Torres, Carmen
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Martínez-Martínez, Luis
Automated antimicrobial susceptibility testing devices are widely implemented in clinical microbiology laboratories in Spain, mainly using EUCAST (European Committee on Antimicrobial Susceptibility Testing) breakpoints. In 2007, a group of experts published recommendations for including antimicrobial agents and selecting concentrations in these systems. Under the patronage of the Spanish Antibiogram Committee (Comité Español del Antibiograma, COESANT) and the Study Group on Mechanisms of Action and Resistance to Antimicrobial Agents (GEMARA) from the Spanish Society of Infectious Diseases and Clinical Microbiology (SEIMC), and aligned with the Spanish National Plan against Antimicrobial Resistance (PRAN), a group of experts have updated this document. The main modifications from the previous version comprise the inclusion of new antimicrobial agents, adaptation of the ranges of concentrations to cover the EUCAST breakpoints and epidemiological cut-off values (ECOFFs), and the inference of new resistance mechanisms. This proposal should be considered by different manufacturers and users when designing new panels or cards. In addition, recommendations for selective reporting are also included. With this approach, the implementation of EUCAST breakpoints will be easier, increasing the quality of antimicrobial susceptibility testing data and their microbiological interpretation. It will also benefit epidemiological surveillance studies as well as the clinical use of antimicrobials aligned with antimicrobial stewardship programs., Los sistemas automáticos utilizados en el estudio de la sensibilidad a los antimicrobianos están introducidos en la mayoría de los laboratorios de Microbiología Clínica en España, utilizando principalmente los puntos de corte del European Committee on Antimicrobial Susceptibility Testing (EUCAST). En 2007, un grupo de expertos publicó unas recomendaciones para incluir antimicrobianos y seleccionar concentraciones en estos sistemas. Bajo el auspicio del Comité Español del Antibiograma (COESANT) y del Grupo de Estudio de los Mecanismos de Acción y Resistencia a los Antimicrobianos (GEMARA) de la Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica (SEIMC) y alineado con el Plan Nacional frente a la Resistencia a los Antibióticos (PRAN), un grupo de expertos ha actualizado dicho documento. Las principales modificaciones realizadas sobre la versión anterior comprenden la inclusión de nuevos agentes antimicrobianos, la adaptación de los rangos de concentraciones para cubrir los puntos de corte clínicos y los puntos de corte epidemiológicos (ECOFF) definidos por el EUCAST, y para la inferencia de nuevos mecanismos de resistencia. Esta propuesta debería ser considerada por los diferentes fabricantes y los usuarios cuando se diseñen nuevos paneles o tarjetas. Además, se incluyen recomendaciones para realizar informes selectivos. Con este enfoque, la implementación de los puntos de corte del EUCAST será más fácil, aumentando la calidad de los datos del antibiograma y su interpretación microbiológica. También será de utilidad para los estudios de vigilancia epidemiológica, así como para el uso clínico de los antimicrobianos, de acuerdo con los programas de optimización de uso de antimicrobianos (PROA).
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Effectiveness of Fosfomycin for the Treatment of Multidrug-Resistant Escherichia coli Bacteremic Urinary Tract Infections, A Randomized Clinical Trial

  • Sojo-Dorado, Jesús
  • López-Hernández, I.
  • Rosso-Fernandez, C.
  • Palacios-Baena, Z.R.
  • Hernández-Torres, A.
  • Merino de Lucas, Esperanza|||0000-0003-3854-4874
  • Escolà-Vergé, Laura|||0000-0002-5608-3090
  • Bereciartua, Elena|||0000-0002-8603-779X
  • García-Vázquez, E.
  • Pintado, Vicente
  • Boix-Palop, Lucía|||0000-0002-4080-0008
  • Natera-Kindelán, C.
  • Sorlí, Luisa|||0000-0001-9562-514X
  • Borrell, Nuria
  • Giner-Oncina, L.
  • Amador-Prous, C.
  • Shaw, Evelyn|||0000-0002-1882-1259
  • Jover-Saenz, Alfredo|||0000-0001-5207-7200
  • Molina, J.
  • Martínez-Alvarez, R.M.
  • Dueñas, C.J.
  • Calvo-Montes, J.
  • Silva, J.T.
  • Cárdenes, M.A.
  • Lecuona, M.
  • Pomar, Virginia|||0000-0002-8473-5834
  • Valiente De Santis, L.
  • Yagüe-Guirao, G.
  • Lobo-Acosta, M.A.
  • Merino-Bohórquez, V.
  • Pascual, A.
  • Rodríguez-Baño, Jesús|||0000-0001-6732-9001
  • Almirante Gragera, Benito|||0000-0002-1189-2361
  • Mirelis, Beatriz
  • Pigrau, Carlos|||0000-0003-4232-4049
  • Viñado, Belén|||0000-0001-6212-5886
  • Puig-Asensio, Mireia|||0000-0002-0722-2218
  • Ardanuy, Carmen|||0000-0003-0225-607X
  • Pujol, Miquel|||0000-0002-6475-6208
The consumption of broad-spectrum drugs has increased as a consequence of the spread of multidrug-resistant (MDR) Escherichia coli. Finding alternatives for these infections is critical, for which some neglected drugs may be an option. To determine whether fosfomycin is noninferior to ceftriaxone or meropenem in the targeted treatment of bacteremic urinary tract infections (bUTIs) due to MDR E coli. Design, Setting, and Participants: This multicenter, randomized, pragmatic, open clinical trial was conducted at 22 Spanish hospitals from June 2014 to December 2018. Eligible participants were adult patients with bacteremic urinary tract infections due to MDR E coli; 161 of 1578 screened patients were randomized and followed up for 60 days. Data were analyzed in May 2021. Patients were randomized 1 to 1 to receive intravenous fosfomycin disodium at 4 g every 6 hours (70 participants) or a comparator (ceftriaxone or meropenem if resistant; 73 participants) with the option to switch to oral fosfomycin trometamol for the fosfomycin group or an active oral drug or parenteral ertapenem for the comparator group after 4 days. Main Outcomes and Measures: The primary outcome was clinical and microbiological cure (CMC) 5 to 7 days after finalization of treatment; a noninferiority margin of 7% was considered. Among 143 patients in the modified intention-to-treat population (median [IQR] age, 72 [62-81] years; 73 [51.0%] women), 48 of 70 patients (68.6%) treated with fosfomycin and 57 of 73 patients (78.1%) treated with comparators reached CMC (risk difference, -9.4 percentage points; 1-sided 95% CI, -21.5 to ∞ percentage points; P =.10). While clinical or microbiological failure occurred among 10 patients (14.3%) treated with fosfomycin and 14 patients (19.7%) treated with comparators (risk difference, -5.4 percentage points; 1-sided 95% CI, -∞ to 4.9; percentage points; P =.19), an increased rate of adverse event-related discontinuations occurred with fosfomycin vs comparators (6 discontinuations [8.5%] vs 0 discontinuations; P =.006). In an exploratory analysis among a subset of 38 patients who underwent rectal colonization studies, patients treated with fosfomycin acquired a new ceftriaxone-resistant or meropenem-resistant gram-negative bacteria at a decreased rate compared with patients treated with comparators (0 of 21 patients vs 4 of 17 patients [23.5%]; 1-sided P =.01). This study found that fosfomycin did not demonstrate noninferiority to comparators as targeted treatment of bUTI from MDR E coli; this was due to an increased rate of adverse event-related discontinuations. This finding suggests that fosfomycin may be considered for selected patients with these infections. ClinicalTrials.gov Identifier: NCT02142751.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Corrigendum, CARB-ES-19 multicenter study of carbapenemase-producing Klebsiella pneumoniae and Escherichia coli from all Spanish provinces reveals interregional spread of high-risk clones such as ST307/OXA-48 and ST512/KPC-3

  • Cañada-García, Javier E.
  • Moure García, Zaira
  • Sola-Campoy, Pedro J.
  • Delgado-Valverde, Mercedes
  • Cano, María E.
  • Gijón, Desirèe
  • González, Mónica
  • Gracia-Ahufinger, Irene
  • Larrosa, María Nieves|||0000-0001-8808-0233
  • Mulet, Xavier
  • Pitart, Cristina|||0000-0002-3083-7915
  • Rivera, Alba|||0000-0002-9709-6162
  • Bou, German|||0000-0001-8837-0062
  • Calvo, Jorge
  • Cantón, Rafael|||0000-0003-1675-3173
  • González-López, Juanjo|||0000-0003-2419-5909
  • Martínez-Martínez, Luis
  • Navarro Risueño, Ferran|||0000-0002-4302-2838
  • Oliver, Antonio|||0000-0001-9327-1894
  • Palacios-Baena, Zaira R.|||0000-0002-1713-6807
  • Pascual, Álvaro
  • Ruiz-Carrascoso, Guillermo
  • Vila Estapé, Jordi|||0000-0002-8025-3926
  • Aracil, Belén
  • Pérez-Vázquez, María
  • Oteo-Iglesias, Jesús|||0000-0003-3327-8263
[This corrects the article DOI: 10.3389/fmicb.2022.918362.].